Y. Nagao

Improvement of metabolic disorders and visceral fat obesity by the beta 3-adrenoceptor agonist (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2 -(3-chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in genetically obese rodents.

N. Murakami, K. Kato, K. Hashimoto, 1996, Biochemical pharmacology.

Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence

T. Akizawa, Masaki Fujioka, Y. Nagao, 2022, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins.

T. Ozawa, J. Hirose, T. Miura, 1998, Biological and Pharmaceutical Bulletin.

[Antipyretic activity of SL-573 (II) (author's transl)].

Y. Yanagi, Y. Nagao, T. Inukai, 1978, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Oral-Mucosal Administration of IFN-α Potentiates Immune Response in Mice

Katsuaki Kato, A. Uemura, Y. Nagao, 1998 .

[Effects of ulinastatin on experimental ulcerative colitis in rats].

K. Mizuguchi, H. Miyata, M. Ban, 1997, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[Mechanism of the anti-osteoarthritic action of ulinastatin in comparison with those of indomethacin and triamcinolone].

T. Oka, K. Ghoda, Y. Nagao, 1992, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Urinary trypsin inhibitor reduces C-X-C chemokine production in rat liver ischemia/reperfusion.

Y. Yamaguchi, M. Ogawa, K. Mori, 2000, The Journal of surgical research.

Human urinary trypsin inhibitor inhibits the activation of pro-matrix metalloproteinases and proteoglycans release in rabbit articular cartilage.

K. Kato, K. Hashimoto, Y. Mori, 1998, Life sciences.